Form D · Biotechnology

Halia Therapeutics, Inc.

Lehi, UT · CIK 0001829255

Offering snapshot reported Aug 31, 2026 · SEC filing

Reported sold
$3.49M
Offering amount: $20M
Investors reported
9
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Aug 17, 2026
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Aug 31, 2026Initial$3,486,474No comparison9SEC filing
Jul 16, 2025Initial$336,833No comparison5SEC filing
Dec 30, 2022Initial$12,223,338No comparison24SEC filing
Feb 17, 2021Initial$4,999,994No comparison5SEC filing
Oct 22, 2020Initial$6,344,990No comparison9SEC filing

Offering details

Securities
Equity, Option to acquire, Other
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-595921
Convertible Promissory Notes

Source: Form D, filed Aug 31, 2026. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Jared Bearss Director
David Bearss Director
Mary Beckerle Director
Jeffrey Burton Executive
Preston Campbell Director
David Checketts Director
John S.K. Kauwe Director
Mike Mccullar Director, Executive
Mike Mc Cullar Director, Executive
Todd Pedersen Director
Gary B. Sabin Director
Jim Savas Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
3900 N. Traverse Mountain Blvd. Suite 100
Lehi, UT, 84043
Phone: 801-842-1652